Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
2.060
+0.020 (0.98%)
Feb 21, 2025, 4:00 PM EST - Market closed
Adagene Revenue
Adagene had revenue of $815.75K in the twelve months ending June 30, 2024, down -96.40% year-over-year. In the year 2023, Adagene had annual revenue of $18.11M with 94.90% growth.
Revenue (ttm)
$815.75K
Revenue Growth
-96.40%
P/S Ratio
111.20
Revenue / Employee
$4,688
Employees
174
Market Cap
91.20M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ADAG News
- 24 days ago - CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso, - GlobeNewsWire
- 4 weeks ago - Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire
- 3 months ago - Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire
- 4 months ago - Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire
- 5 months ago - Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - GlobeNewsWire
- 8 months ago - Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September - GlobeNewsWire
- 9 months ago - Adagene to Present at Investor Conferences in June - GlobeNewsWire
- 11 months ago - Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire